Mydriasis Epidemiology Forecast

DelveInsight’s ‘Mydriasis – Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Mydriasis, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Mydriasis Disease Understanding

Mydriasis is the dilation of the pupil, which may be due to a non-physiological cause such as disease, trauma, drugs usage, or physiological pupillary response. Mydriatic agents are used to dilation of the pupil. They are routinely used to aid examination of the retina and other deep structures of the eye. In general medical practice, the commonest indication for pupil dilation is in the screening of diabetic retinopathy followed by macular degeneration.

The necessity to dilate the pupil to permit adequate fundoscopy has been recognized as early as the 19th century with the invention of the ophthalmoscope. A wide range of mydriatics is currently available. It is a common practice to use a mixture of a mydriatic along with a cycloplegic for diagnostic examinations. Generics of various popular mydriatics widely available in various forms and strengths as per physician requirements.

A lot of research on mydriatics is focused around the fixed-dose combination of mydriatics with other mydriatics, mydriatics with cyclopegics, mydriatics with anesthetics and administration by intracameral injections and eye inserts to facilitate pupil dilation during the cataract surgeries.

Mydriasis Epidemiology

The Mydriasis epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total prevalent cases of Mydriasis patients are increasing in 7MM during the study period, i.e. 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Mydriasis symptoms epidemiology segmented as the Total Prevalent cases of Mydriasis, Gender-specific cases of Mydriasis, Age-specific cases of Mydriasis. The report includes the prevalent scenario of Mydriasis symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Mydriasis Epidemiology

The epidemiology segment also provides the Mydriasis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The total prevalent cases of Mydriasis associated in 7MM countries was found to be 7.98 million in 2017.

• As per the estimates, the United States has the largest prevalent population of Mydriasis.

• Among the EU5 countries, France, along with Germany, had the highest prevalent cases of Mydriasis, followed by Italy. On the other hand, Spain had the lowest prevalent cases, with 0.35 million cases in 2017.

Scope of the Report

• The Mydriasis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.

• The Mydriasis Epidemiology Report and Model provide an overview of the risk factors and global trends of Mydriasis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

• The report provides insight about the historical and forecasted patient pool of Mydriasis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.

• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

• The report assesses the disease risk and burden and highlights the unmet needs of Mydriasis.

• The report provides the segmentation of the Mydriasis epidemiology by Prevalent Cases of Mydriasis in 7MM.

• The report provides the segmentation of the Mydriasis epidemiology by Gender-specific Prevalent Cases of Mydriasis in 7MM.

• The report provides the segmentation of the Mydriasis epidemiology by Age-specific Prevalent Cases of Mydriasis in 7MM.

Report Highlights

• 11-Year Forecast of Mydriasis epidemiology

• 7MM Coverage

• Total Prevalent Cases of Mydriasis

• Prevalent Cases according to segmentation: Gender-specific cases of Mydriasis

• Prevalent Cases according to segmentation: Age-specific cases of Mydriasis

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Mydriasis?

• What are the key findings pertaining to the Mydriasis epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?

• What would be the total number of patients of Mydriasis across the 7MM during the forecast period (2017–2030)?

• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?

• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?

• What is the disease risk, burden and unmet needs of the Mydriasis?

• What are the currently available treatments of Mydriasis?

Reasons to buy

The Mydriasis Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Mydriasis market

• Quantify patient populations in the global Mydriasis market to improve product design, pricing, and launch plans

• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Mydriasis therapeutics in each of the markets covered

• Understand the magnitude of Mydriasis population by its Prevalence cases

• Understand the magnitude of Mydriasis population by its Gender-specific cases

• Understand the magnitude of Mydriasis population by its Age-specific cases

• The Mydriasis epidemiology report and model were written and developed by Masters and PhD level epidemiologists

• The Mydriasis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation

• Disease Risk and Burden

• Risk of disease by the segmentation

• Factors driving growth in a specific patient population

Geographies Covered

• The United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2017–2030

According to the National Eye Institute 2010 estimates, 24.4 million patients were suffering from Cataract. However, population-based incidence data for cataract surgery is advantageous over cross-sectional prevalence data as it more accurately estimates the changes in annual demand. Gollogly et al. estimated the incidence of cataract surgery in the United States in their population study between 2005 and 2011. The overall rate at which incident cataract surgery increased from 2005 through 2011 was unchanged compared with the previous 7-year period, 1998 through 2004. They found that the current incidence rate for cataract surgeries are 1,100 per 100,000 people per year. Studying for 32 years, it was noticed that these incidence rates have now levelled off in the United States.

According to Eurostat data, Cataract surgeries were conducted 4.7 million times in 2017 across the EU Member States. During the past 35 years, life expectancy was increased by 12 years in Western countries. Although cataract surgery has been widely accepted as first-line treatment to prevent blindness in the elderly, there are still enormous variations in the number of procedures carried out in different European countries, ranging from approximately 265 per 100 000 population in Portugal to almost 1400 per 100,000 population in Belgium in 2003 (OECD, 2005).

1.   Key Insights

2.   Organizations

3.   Executive summary

4.   Epidemiology Methodology

5. Mydriasis: Market Overview at a Glance

5.1.  Total Patient Share (%) Distribution of Mydriasis in 2017

5.2.  Total Patient Share (%) Distribution of Mydriasis in 2030

6.   Overview

6.1.  Introduction

6.2.  Causes

6.3.  Physiology

6.4.  Utility in Diagnostics and Therapy

7.   Epidemiology and Patient Population

7.1.  Key Findings

7.2.  Total cases of Mydriasis in 7MM

7.3. United States

7.3.1.     Assumptions and Rationale

7.3.2.     Total Prevalent cases of Mydriasis in the United States

7.3.3.     Gender-specific cases of Mydriasis in the United States

7.3.4.     Age-specific cases of Mydriasis in the United States

7.4. EU5 Countries

7.4.1.     Assumptions and Rationale

7.5. Germany

7.5.1.     Total Prevalent cases of Mydriasis in Germany

7.5.2.     Gender-specific cases of Mydriasis in Germany

7.5.3.     Age-specific cases of Mydriasis in Germany

7.6. France

7.6.1.     Total Prevalent cases of Mydriasis in France

7.6.2.     Gender-specific cases of Mydriasis in France

7.6.3.     Age-specific cases of Mydriasis France

7.7. Italy

7.7.1.     Total Prevalent cases of Mydriasis in Italy

7.7.2.     Gender-specific cases of Mydriasis in Italy

7.7.3.     Age-specific cases of Mydriasis in Italy

7.8. Spain

7.8.1.     Total Prevalent cases of Mydriasis in Spain

7.8.2.     Gender-specific cases of Mydriasis in Spain

7.8.3.     Age-specific cases of Mydriasis Spain

7.9. UK

7.9.1.     Total Prevalent cases of Mydriasis in the United Kingdom

7.9.2.     Gender-specific cases of Mydriasis in the United Kingdom

7.9.3.     Age-specific cases of Mydriasis in the United Kingdom

7.10. Japan

7.10.1.     Assumptions and Rationale

7.10.2.     Total Prevalent cases of Mydriasis in Japan

7.10.3.     Gender-specific cases of Mydriasis in Japan

7.10.4.     Age-specific cases of Mydriasis in Japan

8.   KOL Views

9. Bibliography

10. Appendix

10.1.Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

LIST OF TABLES

Table 1: Mydratic Agents for Diagnostic Purpose

Table 2: Total cases of Mydriasis in 7MM (2017–2030)

Table 3: Total Prevalent cases of Mydriasis in the United States (2017–2030)

Table 4: Gender-specific cases of Mydriasis in the US (2017–2030)

Table 5: Age-specific cases of Mydriasis in the US (2017–2030)

Table 6: Total Prevalent cases of Mydriasis in Germany (2017–2030)

Table 7: Gender-specific cases of Mydriasis in Germany (2017–2030)

Table 8: Age-specific cases of Mydriasis in Germany (2017–2030)

Table 9: Total Prevalent cases of Mydriasis in France (2017–2030)

Table 10: Gender-specific cases of Mydriasis in France (2017–2030)

Table 11: Age-specific cases of Mydriasis in France (2017–2030)

Table 12: Total Prevalent cases of Mydriasis in Italy (2017–2030)

Table 13: Gender-specific cases of Mydriasis in Italy (2017–2030)

Table 14: Age-specific cases of Mydriasis in Italy (2017–2030)

Table 15: Total Prevalent cases of Mydriasis in Spain (2017–2030)

Table 16: Gender-specific cases of Mydriasis in Spain (2017–2030)

Table 17: Age-specific cases of Mydriasis in Spain (2017–2030)

Table 18: Total Prevalent cases of Mydriasis in the United Kingdom (2017–2030)

Table 19: Gender-specific cases of Mydriasis in the UK (2017–2030)

Table 20: Age-specific cases of Mydriasis in the UK (2017–2030)

Table 21: Total Prevalent cases of Mydriasis in Japan (2017–2030)

Table 22: Gender-specific cases of Mydriasis in Japan (2017–2030)

Table 23: Age-specific cases of Mydriasis in Japan (2017–2030)

LIST OF FIGURES

Figure 1: Epidemiology and Market Methodology

Figure 2: Mydriasis Physiology

Figure 3: Total cases of Mydriasis in 7MM (2017–2030)

Figure 4: Total Prevalent cases of Mydriasis in the United States (2017–2030)

Figure 5: Gender-specific cases of Mydriasis in the US (2017–2030)

Figure 6: Age-specific cases of Mydriasis in the US (2017–2030)

Figure 7: Total Prevalent cases of Mydriasis in Germany (2017–2030)

Figure 8: Gender-specific cases of Mydriasis in Germany (2017–2030)

Figure 9: Age-specific cases of Mydriasis in Germany (2017–2030)

Figure 10: Total Prevalent cases of Mydriasis in France (2017–2030)

Figure 11: Gender-specific cases of Mydriasis in France (2017–2030)

Figure 12: Age-specific cases of Mydriasis in France (2017–2030)

Figure 13: Total Prevalent cases of Mydriasis in Italy (2017–2030)

Figure 14: Gender-specific cases of Mydriasis in Italy (2017–2030)

Figure 15: Age-specific cases of Mydriasis in Italy (2017–2030)

Figure 16: Total Prevalent cases of Mydriasis in Spain (2017–2030)

Figure 17: Gender-specific cases of Mydriasis in Spain (2017–2030)

Figure 18: Age-specific cases of Mydriasis in Spain (2017–2030)

Figure 19: Total Prevalent cases of Mydriasis in the United Kingdom (2017–2030)

Figure 20: Gender-specific cases of Mydriasis in the UK (2017–2030)

Figure 21: Age-specific cases of Mydriasis in the UK (2017–2030)

Figure 22: Total Prevalent cases of Mydriasis in Japan (2017–2030)

Figure 23: Gender-specific cases of Mydriasis in Japan (2017–2030)

Figure 24: Age-specific cases of Mydriasis in Japan (2017–2030)

  • Tags:
  • "Mydriasis market
  • Mydriasis market research
  • Mydriasis market insight
  • Mydriasis market trends
  • Mydriasis market forecast
  • Mydriasis market share
  • Mydriasis pipeline drugs
  • Mydriasis treatment algorithm
  • Mydriasis drugs
  • Mydriasis sales forecasting
  • Mydriasis market size
  • Mydriasis disease
  • Mydriasis epidemiology
  • Mydriasis"

Forward to Friend

Need A Quote